Malaria vaccine experts eye prime-boost approaches
Research and development strategy aims to build on success of RTS,S
BETHESDA, Maryland, November 3, 2010 – MVI's research and development strategy aims to build on the success of GlaxoSmithKline Biologicals' RTS,S vaccine candidate that is now in the final stages of development.
In looking toward the development of next-generation malaria vaccines with higher levels of protection, early clinical data strongly support using a “heterologous prime-boost” approach. Under this strategy, when a single application of a malaria vaccine is insufficient, repeated immunizations are performed using different vaccine preparations to sequentially stimulate a better immune response. Essentially, one vaccine primes the immune system to attack malaria while the next one boosts the response. Several prime-boost studies, all in early stages, show some promise. Read more »
- Media advisory: Scientists to report on early data toward dramatically increasing the effectiveness of future malaria vaccines (41 KB PDF)
- Fact sheet: Crucell adenovirus-based malaria vaccine candidate (185 KB PDF)
- Fact sheet: Phase 3 trial of the RTS,S malaria vaccine candidate (243 KB PDF)
- ASTMH session information: Recent progress and future opportunities in developing malaria vaccines employing heterologous prime-boost strategies